Detail akcie Emergent Bio online

Business Summary: Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Emergent Biosolutions Inc revenues decreased 1% to $1.04B. Net loss decreased 75% to $190.6M. Revenues reflect Commercial Products segment decrease of 20% to $398.9M, Non-U.S Government segment decrease of 3% to $633.1M. Lower net loss reflects Impairment of long-lived assets decrease of 91% to $27.2M (expense), Goodwill impairment decrease from $218.2M (expense) to $0K.